Sun Pharmaceutical Industries has been reported to have received US Food and Drug Administration (USFDA)’s approval to sell a drug to treat Osteoporosis, a bone-weakening disease. Currently the drug, Ibandronate Sodium, is marketed by Roche under the brand name Bovina.
Bovina generated annual sales of $82 million in 2012. Further, Sun pharma is the only generic player to have final approval for this product as many other players would be able to sell the drug after its patent expiry on September 2, 2014.
Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
